Ginkgo Bioworks Holdings Inc vs iShares MSCI Malaysia ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.4 (market cap $763.64M), while iShares MSCI Malaysia ETF trades at $26.61 (market cap $256.41M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 3× iShares MSCI Malaysia ETF's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and iShares MSCI Malaysia ETF for 65 Days on average.
| DNA | EWM | |
|---|---|---|
Market Cap | $763.64M | $256.41M |
Volume | 3,204,177 | 111,962 |
Sector | Health | Broad Market / Factor |
52-Week High | $15.83 | $30.42 |
52-Week Low | $5.48 | $25.33 |
Typical Hold Time | 7 Days | 65 Days |
Enterprise Value | $865.59M | — |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
EWM is trading at $26.61, down 1.88% today, with a bearish technical signal from moving averages and neutral oscillators. Key financial ratios such as P/E, P/S, and ROE are unavailable in the provided data, limiting fundamental assessment. The stock lacks recent news coverage, creating uncertainty around current business developments and financial performance.
The outlook for EWM is cautious due to insufficient fundamental data and bearish technical indicators. Investment opportunities hinge on future earnings clarity, while risks include potential weak financials and negative market sentiment. Investors need updated SEC filings or analyst reports to gauge true valuation and growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →